

JUL-08-08

12:17PM

FROM-StoutUxaBuyanMullins

JUL 08 2008 +949-450-1764


T-585


P.001/007

F-094

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/016,850	
	Filing Date	December 14, 2001	
	First Named Inventor	Hughes	
	Group Art Unit	1618	
	Examiner Name	FAY, Z.	
Total Number of Pages in This Submission	7	Attorney Docket Number	D-3004

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> Appeal Communication to TC <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below)</i> Reply to Notice of Non-Compliant Appeal Brief (6 pages)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Stout, Uxa, Buyan & Mullins, LLP		
Signature			
Printed Name	Carlos A. Fisher		
Date	July 8, 2008	Reg. No.	36,510

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO at fax number 571-273-8300, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Shawna Waddell	Date	July 8, 2008

The information contained in this facsimile message is privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service.

RECEIVED
CENTRAL FAX CENTER

JUL 08 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/016,850 Confirmation No. 7435
Applicant : HUGHES et al.
Filed : December 14, 2001
Title : PHARMACEUTICAL CONJUGATES WITH ENHANCED
PHARMACOKINETIC CHARACTERISTICS

TC/A.U. : 1600/1618
Examiner : FAY, Z.

Docket No. : D-3004
Customer No. : 33197

Mail Stop: Appeal Brief
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO NOTICE OF NON-COMPLIANT APPEAL BRIEF

Dear Sir,

Applicants have carefully studied the Notice of Non-Compliant Appeal Brief mailed June 20, 2008. The Notice indicates that under Section V, Summary of the Claimed Subject Matter, Applicants failed to provide a concise reference to where support for independent claims 1 and 16 exists in the specification by page and line number.

In fact, Applicants indicated that each of claims 1 and 16 was supported by the specification at pages 2-4, which citation includes all lines of the indicated pages. Applicants therefore disagree that the Appeal Brief filed June 9, 2008 was, in fact, non-compliant. However, in

CERTIFICATE OF MAILING OR FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office fax number 571-273-8300, or mailed by first class mail to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Date: JULY 8, 2008

Signature: Shawna Waddell
Name: Shawna Waddell

JUL 08 2008


Page 2 of 6

order to save the time that would be required to petition this issue, and in accordance with Manual of Patent Examining Procedure §1205.03(B) Applicants submit with this communication an Amended Summary of Claimed Subject Matter, in which claims 1 and 16 are indicated as being supported by the specification at page 2, line 33 to page 5, line 4.

Accordingly, Applicants believe this issue has been addressed and ask that the Appeal Brief be passed to Board of Patent Appeals and Interferences for decision.

This communication is being filed within the one month period for response to the June 20, 2008 Notice set forth therein; thus no fee is thought due in connect with this communication. However, if any other fee is due, or to credit any overpayment, Applicants hereby authorize the Commissioner to use Deposit Account 50-4004.

Respectfully submitted,



Carlos A. Fisher
Reg. No. 36,510
Attorney for Applicants

Stout, Uxa, Buyan & Mullins LLP
4 Venture
Suite 300
Irvine, California 92618
(949)-450-1750

RECEIVED
CENTRAL FAX CENTER

JUL 08 2008

AMENDED SUMMARY OF CLAIMED SUBJECT MATTER

Claim 1 is drawn to a topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate, wherein the carrier comprises an ophthalmically useful therapeutic component (TC) covalently coupled in a specific manner to an efficacy enhancing component (EEC) effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye. The efficacy-enhancing component comprises a specifically recited generic chemical structure. This claim is supported by the specification at, e.g., pages 2, line 33 to page 5, line 4.

Claim 2 is drawn to the composition of claim 1 in which the TC and EEC are joined directly by a covalent bond and the carrier comprises a liquid. Support for this claim is as indicated for claim 1; in addition, support can be found at page 3, lines 21 and 22 and page 17, lines 9-11.

Claim 3 is drawn to the composition of claim 1 in which the TC and EEC are joined by a linker. Support for this claim is as indicated for claim 1; in addition, support can be found at page 3, lines 22-24.

Claim 4 is drawn to the composition of claim 1 wherein R1 and R2 are H and R3 is a linker. Support for this claim is as indicated for claim 1; in addition, support can be found at page 12, lines 22 and 23.

Page 4 of 6

Claim 5 is drawn to the composition of claim 1 wherein the efficacy enhancing component is a memantine. Support for this claim is as indicated for claim 1; in addition, support can be found at page 12, lines 23 and 24.

Claim 6 is drawn to the composition of claim 1 wherein the linker is selected from a specifically indicated Markush group of linkers. Support for this claim is as indicated for claim 1; in addition, support can be found at page 4, lines 1-31.

Claim 8 is drawn to the composition of claim 1 wherein the therapeutic component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, and mixtures thereof. Support for this claim is as indicated for claim 1; in addition, support can be found at page 9, line 31 to page 10, line 3.

Claim 9 is drawn to the composition of claim 1 wherein the efficacy-enhancing component comprises a memantine, and the conjugate further comprises a linker covalently joining the therapeutic component and the memantine in a specific manner. Support for this claim is as indicated for claim 1; in addition, support can be found at page 12, lines 23 and 24 and page 3, lines 22-24.

Claim 11 is drawn to the composition of claim 8 wherein the efficacy-enhancing component comprises a memantine, and the conjugate further comprises a linker joining the therapeutic component and the memantine. Support for this claim is as indicated for claim 8; in addition, support can

Page 5 of 6

be found at page 12, lines 23 and 24 and page 3, lines 22-24 and page 14, lines 32-34.

Claim 12 is drawn to the composition of claim 1 wherein the therapeutic component and the efficacy enhancing component disassociate under physiological conditions. Support for this claim is as indicated for claim 1; in addition, support can be found at page 14, lines 4-6.

Claim 14 is drawn to the composition of claim 1 wherein the conjugate has an aqueous solubility, a partition coefficient and/or an affinity for melanin that is greater relative to a compound comprising the same therapeutic component which is not joined to an efficacy enhancing component. Support for this claim is as indicated for claim 1; in addition, support can be found at page 11, lines 3-7 and Example 6.

Claim 15 is drawn to the composition of claim 1 wherein the conjugate is a salt. Support for this claim is as indicated for claim 1; in addition, support can be found at page 11, line 15-28.

Claim 16 is drawn to a topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate, wherein the carrier comprises an ophthalmically useful therapeutic component (TC) covalently coupled via a linker to an efficacy enhancing component (EEC) effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye. The efficacy-enhancing component comprises a specifically recited generic chemical

Page 6 of 6

structure, as is the linker. This claim is supported by the specification at, e.g., pages 2, line 33 to page 5, line 4.

Claim 24 is drawn to a topical ophthalmic composition comprising a carrier and a pharmaceutical conjugate, wherein the carrier comprises an ophthalmically useful therapeutic component (TC), comprising a ophthalmically useful quinoxaline component, covalently coupled via a linker to an efficacy enhancing component (EEC) effective in delivering the conjugate to a posterior portion of an eye of an individual when the composition is topically administered to the eye. The efficacy-enhancing component and linker each comprise specifically recited generic chemical structures. This claim is supported by the specification at, e.g., pages 2, line 33 to page 5, line 4 and page 9, line 31 to page 10, line 3.

Claim 25 is drawn to the composition of claim 24 wherein the therapeutic component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, and mixtures thereof. This claim is supported by the specification at, e.g., pages 2, line 33 to page 5, line 4 and page 9, line 31 to page 10, line 3.

Claim 26 is drawn to the composition of claim 25 wherein the therapeutic component comprises brimonidine tartrate. Support for this claim is as indicated for claim 25 and at page 17, line 32.